STOCK TITAN

Corcept Therapeutics Inc - CORT STOCK NEWS

Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.

Corcept Therapeutics Inc. (NASDAQ: CORT) is a commercial-stage pharmaceutical company dedicated to the discovery and development of innovative medications that target the underlying effects of abnormal cortisol levels. Cortisol, a hormone essential for various bodily functions, can become dysregulated and contribute to a range of serious health conditions, including metabolic disorders, oncologic diseases, and neuropsychiatric illnesses. Corcept leverages its deep scientific expertise to address these challenges by developing drugs that modulate the glucocorticoid receptor (GR), a key mediator of cortisol's effects.

Core Business Areas

Corcept's business model is centered on the research, development, and commercialization of GR antagonists. The company’s flagship product, mifepristone, is approved for the treatment of hypercortisolism in certain conditions. Beyond this, Corcept has built an extensive pipeline of over 300 proprietary molecules, each designed to selectively block the GR without affecting the progesterone receptor. This specificity minimizes side effects and enhances therapeutic potential.

Addressing Unmet Medical Needs

Corcept’s innovative compounds are being evaluated in clinical trials for their ability to treat a variety of severe and life-threatening conditions. These include:

  • Hypercortisolism: A disorder characterized by excessive cortisol levels, often linked to Cushing's syndrome.
  • Oncologic Applications: Advanced ovarian cancer, prostate cancer, and other malignancies where cortisol plays a role in disease progression.
  • Neuropsychiatric Disorders: Conditions such as post-traumatic stress disorder (PTSD), mild cognitive impairment, and Alzheimer’s disease.
  • Metabolic Diseases: Non-alcoholic steatohepatitis (NASH) and other metabolic syndromes influenced by cortisol dysregulation.

Scientific Approach and Differentiation

What sets Corcept apart in the competitive pharmaceutical landscape is its singular focus on GR antagonism. Unlike traditional therapies that may broadly target hormonal pathways, Corcept’s compounds are designed to selectively block the GR, thereby mitigating the adverse effects of excess cortisol while preserving other hormonal functions. This approach is supported by extensive scientific literature and represents a promising avenue for treating diseases with high unmet medical needs.

Market Position and Growth Potential

Operating in the dynamic pharmaceutical industry, Corcept occupies a niche position as a pioneer in cortisol modulation therapies. Its focus on conditions with limited treatment options provides a strategic advantage, as does its robust pipeline of proprietary molecules. However, the company faces challenges typical of the sector, including regulatory approvals, competition from larger pharmaceutical firms, and the inherent risks of clinical trial outcomes. Despite these hurdles, Corcept’s unique scientific approach and targeted focus position it as a significant player in its field.

Commitment to Innovation

Corcept’s commitment to advancing medical science is evident in its investment in research and development. By exploring the role of cortisol in various diseases and developing compounds that address these mechanisms, the company aims to deliver transformative therapies that improve patient outcomes. Its strategic focus on unmet medical needs underscores its potential to make a lasting impact on the healthcare landscape.

Conclusion

Corcept Therapeutics Inc. exemplifies the intersection of scientific innovation and patient-focused care. Through its pioneering work in cortisol modulation, the company addresses some of the most pressing challenges in modern medicine. With a strong foundation in research, a growing pipeline of proprietary compounds, and a commitment to addressing unmet medical needs, Corcept is well-positioned to contribute significantly to the pharmaceutical industry.

Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) has announced it will release its third quarter financial results and provide a corporate update on October 30, 2024. The company will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on the same day. Participants must pre-register to receive dial-in details and a unique access PIN. A listen-only webcast option will also be available, with a replay accessible through the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences earnings
-
Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) reported strong Q2 2024 financial results, with revenue of $163.8 million, a 39% increase year-over-year. The company raised its 2024 revenue guidance to $640 – $670 million. Net income per share was $0.32, up from $0.25 in Q2 2023. Cash and investments stood at $492.5 million.

Corcept's clinical development pipeline showed progress, with positive results from the GRACE trial for relacorilant in Cushing's syndrome. The company plans to submit a New Drug Application for relacorilant in Q4. The CATALYST study revealed a 24% prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Results from several late-stage trials, including ROSELLA for ovarian cancer and DAZALS for ALS, are expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
-
Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) has announced it will release its second quarter financial results and provide a corporate update on July 29, 2024. The company will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on the same day. Participants must register in advance to receive a dial-in number and unique access PIN. A listen-only webcast will also be available. A replay of the call will be accessible on the Investors / Events section of Corcept.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
conferences earnings
Rhea-AI Summary

Corcept Therapeutics announced results from the prevalence phase of their CATALYST clinical trial at the American Diabetes Association’s 84th Scientific Sessions.

The trial enrolled 1,055 patients with difficult-to-control type 2 diabetes across 36 U.S. sites, making it the largest study of its kind. The results showed a 24% prevalence rate of hypercortisolism among these patients, a higher figure than previously assumed.

Hypercortisolism was notably common in patients with cardiovascular issues and those needing multiple medications for diabetes and hypertension control.

This new data may lead to better diagnosis and treatment strategies for hypercortisolism, a serious condition often overlooked in type 2 diabetes management.

Details of the treatment phase, where eligible patients received either Korlym or a placebo, are expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) announced that results from the Phase 3 GRACE trial of relacorilant, a selective cortisol modulator for treating hypercortisolism (Cushing’s syndrome), will be presented at two major conferences in June 2024. The presentations will take place at the Endocrine Society (ENDO) annual meeting in Boston on June 3, and at the Heart in Diabetes (HiD) conference in Philadelphia on June 7. Key findings will be shared by Dr. Rosario Pivonello and Dr. Ralph DeFronzo, highlighting the impact of relacorilant on hypertension and hyperglycemia. Detailed results will be accessible on Corcept’s website post-events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
-
Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) announced positive results from its Phase 3 GRACE trial of relacorilant for treating hypercortisolism (Cushing’s syndrome). The trial met its primary endpoint, showing significant improvements in hypertension, hyperglycemia, and other symptoms. In the randomized withdrawal phase, patients receiving relacorilant had a notably lower loss of blood pressure control compared to those on placebo (odds ratio: 0.17; p-value: 0.02). The drug was well-tolerated, with no significant safety differences observed. Corcept plans to submit a New Drug Application in Q3, with additional data presentations scheduled for June.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.86%
Tags
Rhea-AI Summary

Corcept Therapeutics Incorporated reported strong financial results for the first quarter of 2024, with a revenue of $146.8 million, a 39% increase from the same period in 2023. The company raised its 2024 revenue guidance to $620 - $650 million and reported a net income per common share of $0.25. Corcept continues to focus on developing medications for various disorders by modulating the effects of cortisol. The company highlighted record numbers of new prescribers and patients for its drug Korlym in the first quarter, showcasing its growing presence in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
-
Rhea-AI Summary

Corcept Therapeutics Incorporated has completed enrollment in the Phase 4 CATALYST trial, the largest study ever conducted to establish the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Approximately 25% of the over 1,000 patients enrolled were identified as having hypercortisolism, a higher rate than previously assumed. Final prevalence data will be shared at the American Diabetes Association’s 84th Scientific Sessions in June, with treatment data expected by year-end. The findings from CATALYST aim to improve the identification and treatment of patients with hypercortisolism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
Rhea-AI Summary
Corcept Therapeutics (NASDAQ: CORT) will unveil its first quarter financial results and share a corporate update on May 1, 2024. A conference call is scheduled for 5:00 p.m. Eastern Time. Participants need to register in advance to receive the dial-in number and access PIN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
Rhea-AI Summary
Corcept Therapeutics announces positive results from the open-label portion of the pivotal Phase 3 GRACE trial for relacorilant in patients with Cushing’s syndrome. The trial showed significant improvements in hypertension, hyperglycemia, and other key endpoints without adverse effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags

FAQ

What is the current stock price of Corcept Therapeutics (CORT)?

The current stock price of Corcept Therapeutics (CORT) is $74.45 as of April 4, 2025.

What is the market cap of Corcept Therapeutics (CORT)?

The market cap of Corcept Therapeutics (CORT) is approximately 7.9B.

What does Corcept Therapeutics specialize in?

Corcept Therapeutics specializes in developing drugs that modulate the effects of cortisol to treat metabolic, oncologic, and neuropsychiatric disorders.

What is Corcept’s flagship product?

Corcept’s flagship product is mifepristone, approved for treating hypercortisolism in specific conditions.

What makes Corcept’s approach unique?

Corcept focuses on selective glucocorticoid receptor (GR) antagonism, which targets cortisol's effects without affecting other hormonal pathways.

What diseases are Corcept’s compounds being developed to treat?

Corcept’s compounds are being developed to treat hypercortisolism, advanced cancers, PTSD, Alzheimer’s disease, and metabolic disorders like NASH.

How does Corcept generate revenue?

Corcept generates revenue through the commercialization of its approved drugs and ongoing development of its proprietary pipeline.

What challenges does Corcept face in its industry?

Corcept faces challenges such as regulatory approvals, competition from larger pharmaceutical companies, and the risks inherent in clinical trials.

What is the significance of glucocorticoid receptor antagonism?

Glucocorticoid receptor antagonism helps mitigate the adverse effects of excess cortisol, offering potential treatments for various serious conditions.

What is Corcept’s competitive advantage?

Corcept’s competitive advantage lies in its focus on cortisol modulation and its extensive pipeline of proprietary GR antagonists.

What industries does Corcept Therapeutics operate in?

Corcept operates in the pharmaceutical and biotechnology industries, focusing on drug development for unmet medical needs.

How does Corcept contribute to addressing unmet medical needs?

Corcept develops innovative therapies targeting diseases with limited treatment options, such as hypercortisolism and advanced cancers.
Corcept Therapeutics Inc

Nasdaq:CORT

CORT Rankings

CORT Stock Data

7.87B
93.36M
11.44%
81.8%
15.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY